𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of restless leg syndrome with pergolide—an open clinical trial

✍ Scribed by Juliane Winkelmann; Thomas C. Wetter; Karen Stiasny; Wolfgang H. Oertel; Claudia Trenkwalder

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
331 KB
Volume
13
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Dopaminergic treatment with levodopa (L‐dopa) has been proven as the treatment of first choice in patients with restless leg syndrome (RLS). Augmentation of symptoms and end‐of‐dose rebound phenomena under L‐dopa/decarboxylase inhibitor treatment present major problems in some patients. To evaluate the efficacy of pergolide in RLS, we treated 15 patients suffering from severe RLS, who had previously experienced an augmentation of symptoms under long‐term treatment with L‐dopa, in an open clinical trial with pergolide. All patients reported an improvement of their RLS symptoms. Our study shows that pergolide, if administered at a mean dose of 0.4 mg in combination with domperidone, is a very effective drug in the treatment of sleep disturbances and daytime symptoms associated with RLS, and does not cause any serious side effects during the observation period of 6 months.

📜 SIMILAR VOLUMES

Augmentation of restless legs syndrome w
Augmentation of restless legs syndrome with long-term tramadol treatment
✍ Roberto Vetrugno; Chiara La Morgia; Roberto D'Angelo; Daniela Loi; Federica Prov 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

## Abstract Restless legs syndrome (RLS) augmentation, defined as a kind of suppression of the circadian rhythm of the disease in which sensory and motor symptoms appear earlier during the day (and over previously unaffected body parts), with a progressive phase advance until, backwards, the sympto

Treatment of restless legs syndrome with
Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine
✍ Frithjof Tergau; Stephan Wischer; Christian Wolf; Walter Paulus 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

## Abstract An open pilot study with the dopamine agonist α‐dihydroergocryptine (DHEC) was conducted in 16 patients with idiopathic restless legs syndrome (RLS) over a period of 5 weeks. Following a drug‐free interval of 1 week, the patients were treated with daily doses of 10 to 40 mg DHEC. As com

Assessment of restless legs syndrome—Met
Assessment of restless legs syndrome—Methodological approaches for use in practice and clinical trials
✍ Ralf Kohnen; Richard P. Allen; Heike Benes; Diego Garcia-Borreguero; Wayne A. He 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

The Restless Legs Syndrome (RLS) is a sensorimotor disorder that has only recently been extensively investigated by validated methods. Following the first presentation of diagnostic criteria by the International RLS Study Group in 1995, several methods were specifically developed for clinical trials

Clinical trials in restless legs syndrom
Clinical trials in restless legs syndrome—Recommendations of the European RLS Study Group (EURLSSG)
✍ Claudia Trenkwalder; Ralf Kohnen; Richard P. Allen; Heike Benes̆; Luigi Ferini-S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

The European Restless Legs Syndrome (RLS) Study Group (EURLSSG) is an association of European RLS experts who are actively involved in RLS research. A major aim of the Study Group is the development and continuous improvement of standards for diagnosis and treatment of RLS. Several members developed

Controlled withdrawal of pramipexole aft
Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
✍ Claudia Trenkwalder; Karin Stiasny-Kolster; Andreas Kupsch; Wolfgang H. Oertel; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract Although dopamine agonists are becoming first‐line therapy for restless legs syndrome (RLS), few reports describe treatment periods exceeding 12 weeks. Here, 150 RLS patients who had responded to pramipexole during a 6‐month run‐in period (mean dose, 0.50 mg) were randomly assigned to r

One-year treatment with standard and sus
One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome?
✍ Claudia Trenkwalder; Victor Collado Seidel; Jörg Kazenwadel; Thomas C. Wetter; W 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract To investigate the long‐term efficacy and safety of sustained‐release (SR) in combination with regular‐release (RR) levodopa/benserazide in the treatment of restless legs syndrome (RLS), an open‐label, prospective, extension study of a preceding double‐blind crossover trial was performe